Senti Biosciences (SNTI) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
13 Oct, 2026Executive summary
The virtual annual meeting was adjourned on October 8, 2026, without conducting business, despite a quorum; it is scheduled to reconvene October 15 at 8:00 a.m. Pacific time.
Voting matters and shareholder proposals
The adjournment allows more time to solicit votes in favor of the Merger Agreement Proposal; proposals are unchanged and polls remain open.
The record date remains September 23, 2026; stockholders who already voted and do not wish to change their vote need take no action.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Senti Biosciences
- Merger approval sought with Celadon, with stockholders to receive milestone-based CVRs.SNTI
Proxy filing - Merger approval, CVRs, reverse split, and major share issuance up for stockholder vote.SNTIProxy filing
- Amendment updates auditor consent for a public offering, with all signatures finalized.SNTIRegistration filing
- Offering of 25.6M shares (82.1% of stock) triggers major dilution and strategic realignment.SNTIRegistration filing
- Stockholders will receive contingent value rights in a merger, with future payments tied to SENTI-202 milestones.SNTIProxy filing
- Convertible note and equity commitment secured, with shareholder vote pending on merger and CVR.SNTIProxy filing
- Amended financing and merger plans address Nasdaq compliance and offer contingent value rights.SNTIProxy filing
- Shareholders to vote on $4M convertible notes and potential $60M payout tied to SENTI-202 milestones.SNTIProxy filing
- Q2 net loss narrowed, cash fell, and a merger will leave only early-stage assets and CVRs for shareholders.SNTIQ2 2026